Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Posted: February 24, 2023 at 12:14 am
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact –
Continue reading here:
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Posted in Global News Feed
Comments Off on Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Posted: February 24, 2023 at 12:14 am
Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid Absorption Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid Absorption
Read the original:
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Posted in Global News Feed
Comments Off on Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Posted: February 24, 2023 at 12:14 am
Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR treatment-naïve, FGFR2-fusion cholangiocarcinoma patients & announced anticipated registrational path
Read more here:
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Posted in Global News Feed
Comments Off on Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Posted: February 24, 2023 at 12:14 am
Initiated ReSPECT-GBM Phase 2 and ReSPECT- LM Phase 1 trials for CNS cancers
See original here:
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Posted in Global News Feed
Comments Off on Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Posted: February 24, 2023 at 12:14 am
Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications
See the rest here:
Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Posted in Global News Feed
Comments Off on Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Tonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell
Posted: February 24, 2023 at 12:14 am
CHATHAM, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of R. Newcomb Stillwell to its Board of Directors, to be effective as of March 15, 2023.
Continued here:
Tonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell
Posted in Global News Feed
Comments Off on Tonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results
Posted: February 24, 2023 at 12:14 am
— Company expects to announce data for Factor VIII expression in non-human primates in 2023
Here is the original post:
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results
Posted in Global News Feed
Comments Off on Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
Posted: February 24, 2023 at 12:14 am
FREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has closed a funding agreement for gross proceeds of $3.175 million (the "Investment") with Lind Global Fund II, LP, an investment fund managed by The Lind Partners (together “Investor” or “Lind”), a New York-based institutional fund manager.
Read more here:
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
Posted in Global News Feed
Comments Off on ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
Posted: February 24, 2023 at 12:14 am
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer –
Excerpt from:
Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
Posted in Global News Feed
Comments Off on Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
Posted: February 24, 2023 at 12:14 am
Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs
View original post here:
Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
Posted in Global News Feed
Comments Off on Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million